Allakos Inc

Allakos — Investor Presentation (September 2022)

41 slides from Allakos's investor presentation, Sep 19, 2022

  1. Slide 1: Corporate Presentation September 2022

    Corporate Presentation September 2022 Exhibit 99.2 Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Disease

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); business strategy; plans and obje

  3. Slide 3: Novel Targets for the Treatment of Inflammatory Diseases

    Novel Targets for the Treatment of Inflammatory Diseases Lirentelimab depletes eosinophils and inhibits mast cells Safety profile characterized in hundreds of patients Lirentelimab (anti-Siglec-8) AK006 (anti-Siglec-6) selectively and potently inhibits mast cell activation, including KIT-mediated si

  4. Slide 4: Mast Cells and Eosinophils Are Key Drivers of Inflammatory Disease

    Mast Cells and Eosinophils Are Key Drivers of Inflammatory Disease IL-13

  5. Slide 5: Allakos Pipeline

    Antibody Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Milestone Atopic Dermatitis Initiated; Topline expected 2H 2023 Chronic Spontaneous Urticaria Initiated; Topline expected 2H 2023 AK006 (Anti-Siglec-6) Inflammatory Diseases Expected initiation of Phase 1 trial in 1H 2023 in h

  6. Slide 6: Significant Opportunity Exists to Treat Inflammation & Immunology

    Significant Opportunity Exists to Treat Inflammation & Immunology Rheumatoid Arthritis Psoriasis Ulcerative Colitis Crohn’s Disease Asthma Atopic Dermatitis Chronic Spontaneous Urticaria Eosinophilic Gastrointestinal Disorders 2021 Estimated WW Sales ~$30 bn ~$24 bn ~$8 bn ~$14 bn ~$8 bn ~$5 bn ~$1.

  7. Slide 7: Lirentelimab: Siglec-8 mAb That Depletes Eosinophils and Inhibits Mast Cells

    Lirentelimab: Siglec-8 mAb That Depletes Eosinophils and Inhibits Mast Cells

  8. Slide 8: Lirentelimab: Siglec-8 mAb That Depletes Eosinophils and Inhibits Mast Cells

    Lirentelimab: Siglec-8 mAb That Depletes Eosinophils and Inhibits Mast Cells Lirentelimab shows eosinophil depletion and mast cell inhibition in humans: Rapid and sustained depletion of eosinophils via ADCC Inhibition of mast cell activation via multiple stimuli including IL-33, TSLP, IgE, MRGPRX-2,

  9. Slide 9: Sustained Depletion of Blood Eosinophil Counts

    Sustained Depletion of Blood Eosinophil Counts Phase 2 ENIGMA1 Study and Open-Label Extension Time on Treatment (Weeks)b Dose Eosinophilsa (Cells/µL) Median ±IQR 800 500 250 0 BL 56 53 55 53 53 55 53 50 48 46 44 44 36 33 n SOURCE: Dellon ES, et al. New England Journal of Medicine. 2020;383:1624-1634

  10. Slide 10: Lirentelimab Broadly Inhibits Mast Cell Activation

    Lirentelimab Broadly Inhibits Mast Cell Activation Lirentelimab Inhibits IL-33-Mediated Mast Cell Activation Transcriptome of IL-33-Activated Mast Cells Phospho-Proteome of IgE-Activated Mast Cells SOURCE: Schanin, J et al. Mucosal Immunology. 2020: 366-376 SOURCE: Korver, W et al. Frontiers in Immu

  11. Slide 11: Lirentelimab for Chronic Spontaneous Urticaria

    Lirentelimab for Chronic Spontaneous Urticaria

  12. Slide 12: Phase 2a Chronic Urticaria Study

    Phase 2a Chronic Urticaria Study Open-label study in patients with Chronic Urticaria (CU) Uncontrolled CU (UCT <12) at the time of enrollment Diagnosis of CU for at least three months, refractory to antihistamine treatment on 1 to 4x labeled dosage 45 patients – 4 cohorts Omalizumab-naïve Chronic Sp

  13. Slide 13: Symptom Improvement by UAS7 with Lirentelimab in CSU

    Symptom Improvement by UAS7 with Lirentelimab in CSU Omalizumab Naïve (n=13) Baseline Week 22 Omalizumab Refractory Receiving All 6 Doses (n=7) UAS7 is a validated patient-reported outcome recording the intensity of pruritus (Weekly Itch Severity Score) and the number of wheals (Weekly Hives Severit

  14. Slide 14: Lirentelimab UAS7 Response in Omalizumab Naïve CSU

    Endpoint Baseline Omalizumab Naïve Week 22 Average UAS7 Score 18.5 4.6 (-75%) Patients with UAS7 ≤ 6 0 (0%) 8/13 (62%) Patients with UAS7 = 0 0 (0%) 7/13 (54%) Patients with ISS7 = 0 0 (0%) 7/13 (54%) Patients with HSS7 = 0 0 (0%) 10/13 (77%) Lirentelimab UAS7 Response in Omalizumab Naïve CSU UAS7 i

  15. Slide 15: Lirentelimab UAS7 Response in Omalizumab Refractory CSU

    Lirentelimab UAS7 Response in Omalizumab Refractory CSU % Change in UAS7 28 24 36 29 35 26 21 0 5 8 8 16 14 27 BL= Week 22= Omalizumab Refractory Receiving All 6 Doses (n=7) SOURCE: Altrichter S et al. J Allergy Clin Immunol. 2022 Sep;150(3):736-737

  16. Slide 16: High UCT Response Rate Observed in Multiple Forms of Urticaria

    High UCT Response Rate Observed in Multiple Forms of Urticaria Indication UCT Baseline UCT Week 22 UCT Complete Responders Chronic Spontaneous Urticaria Naïve (n=13) Xolair Refractory (n=7)1 3.2 3.1 14.2 11.4 92% 57% Cholinergic Urticaria (n=11) 5.4 11.8 82% Symptomatic Dermographism (n=10) 5.7 9.1

  17. Slide 17: Phase 2b Chronic Spontaneous Urticaria Study

    Phase 2b Chronic Spontaneous Urticaria Study Multi-center, randomized, DB, placebo-controlled Active moderate-to-severe symptoms CSU diagnosis with onset ≥6 months prior to screening Diagnosis of CSU refractory to antihistamines Presence of itch and hives despite current use of antihistamines UAS7 s

  18. Slide 18: Biologics for Chronic Spontaneous Urticaria

    Biologics for Chronic Spontaneous Urticaria Drug Name MOA UAS7 Response Opportunity Xolair® (omalizumab) Anti-IgE mAb Dose Group1 150 mg 300 mg Placebo >50% of patients continue to have symptoms Black box for anaphylaxis1 UAS7 -14.4 (-48%) -20.8 (-66%) -8.0 (-26%) UAS7=0 15% 36% 9% Dupixent® (dupilu

  19. Slide 19: Lirentelimab for Atopic Dermatitis

    Lirentelimab for Atopic Dermatitis

  20. Slide 20: Biopsies of Atopic Dermatitis Lesions Show Mast Cell and Eosinophil Activity

    Biopsies of Atopic Dermatitis Lesions Show Evidence of Mast Cell and Eosinophil Activity Immune Cell Numbers Disease Biomarkers Mast Cell Activation CCL26 / Eotaxin-3 CCL17 / TARC CPA3 Eosinophils Mast Cells SOURCE: Youngblood, BA et al JCI Insights 2019: 126219; Schanin, J et al Mucosal Immunology

  21. Slide 21: Lirentelimab Reduced Clinically-Relevant Cytokines in Phase 1 Allergic Conjunctivitis Study

    Lirentelimab Reduced Clinically-Relevant Cytokines in Phase 1 Severe Allergic Conjunctivitis Study SOURCE: Anesi, S. et al. Journal of Allergy and Clinical Immunology 2022 Ocular Inflammation via Tear Cytokines Last Dose Last Dose Last Dose Last Dose IL-4 IL-13 CCL26 / Eotaxin-3 CCL3 / MIP-1

  22. Slide 22: Lirentelimab Improved Atopic Dermatitis Symptoms in ENIGMA2 and SAC Studies

    Lirentelimab Improved Atopic Dermatitis Symptoms in ENIGMA2 and SAC Studies Median % Change from BL Weeks 21-22 Placebo (n=4) Lirentelimab (n=5) Patients with Atopic Dermatitis in Open-Label SAC Study Lirentelimab (n=11) Patients with Atopic Dermatitis in ENIGMA2 EG/EoD Study Patients with comorbid

  23. Slide 23: Phase 2b Atopic Dermatitis Study Design

    Phase 2 Atopic Dermatitis Study Design Multi-center, randomized, DB, placebo-controlled Chronic disease that has been present ≥3 years EASI score ≥16 Involvement of ≥10% of body surface area IGA score ≥3 Inadequate control by topical treatments Includes patients with prior biologics treatment 130 ad

  24. Slide 24: Atopic Dermatitis Landscape

    Atopic Dermatitis Landscape Drug Name MOA EASI-75 Response IGA Response Opportunity Dupixent® (dupilumab) Anti IL-4/IL-13R mAb 44% – 51% vs. 12 – 15% placebo1 36 – 38% vs. 9 – 10% placebo1 >50% of patients continue to have symptoms Conjunctivitis in ~26%2 Q2W dosing1 Adbry™ (tralokinumab) Anti IL-13

  25. Slide 25: Lirentelimab for Eosinophilic Gastrointestinal Disorders

    Lirentelimab for Eosinophilic Gastrointestinal Disorders

  26. Slide 26: EGID Biopsies Have Elevated and Activated Eosinophils & Mast Cells

    EGID Biopsies Have Elevated and Activated Eosinophils & Mast Cells Eosinophils and mast cells both appear to play a pathogenic role in EGIDs Lirentelimab is a novel investigational therapy that directly targets eosinophils and mast cells SOURCE: Youngblood B, et al. JCI Insights. 2019 Eosinophils 10

  27. Slide 27: ENIGMA1 Phase 2: Histology and Symptom Results

    Histology Results Symptom Results Proportion of Patients Achieving EG/EoD Histologic Response1 at End of Treatment ENIGMA1 Phase 2 primary endpoint was mean percent change in gastroduodenal eosinophils, symptomatic endpoint was percentage change in TSS-8 1.)Eosinophil response criteria: mean ≤4 eos/

  28. Slide 28: ENIGMA2 Phase 3: Co-Primary Endpoints

    ENIGMA2 Phase 3: Co-Primary Endpoints Histology Co-Primary Endpoint Symptom Co-Primary Endpoint Proportion of Patients Achieving EG/EoD Histologic Response1 at Week 24 Lirentelimab Placebo * (77/91) (4/89) % of Patients Lirentelimab (n=91) Placebo (n=89) 27.7 29.5 BL TSS = Absolute Change in Total S

  29. Slide 29: Lirentelimab for Eosinophilic Gastrointestinal Disorders

    Lirentelimab for Eosinophilic Gastrointestinal Disorders Despite positive Phase 2 results (ENIGMA 1), the Phase 3 study in EG and/or EoD (ENIGMA2) and Phase 3 study in EoD (EoDyssey) achieved histologic co-primary endpoints but missed symptomatic co-primary endpoints. Post-hoc analyses suggest that

  30. Slide 30: Lirentelimab Safety

    Lirentelimab Safety

  31. Slide 31: Safety Summary

    Safety Summary Intravenous (IV) lirentelimab has been administered in >750 patients, and with >300 patients exposed to one year Most common adverse event has been infusion-related reactions (IRR) IRRs commonly associated with IV administered ADCC antibodies No long-term safety findings to date Subcu

  32. Slide 32: AK006: Siglec-6 mAb that Selectively and Potently Inhibits Mast Cells

    AK006: Siglec-6 mAb that Selectively and Potently Inhibits Mast Cells

  33. Slide 33: AK006: Siglec-6 mAb That Inhibits and Depletes Mast Cells

    AK006 is a humanized IgG1 agonistic Siglec-6 mAb that selectively inhibits mast cells and reduces their numbers: Represents the first mast cell-specific antibody in development Inhibition of both IgE-dependent and IgE-independent mast cell activation Reduction of mast cells via Fc-dependent mechanis

  34. Slide 34: AK006 Associates with Inhibitory Molecules

    AK006 Associates with Inhibitory Molecules Mast Cell Inhibition AK006 SHP-1 AK006/SHP-1

  35. Slide 35: AK006 Inhibits Mast Cell Activation in Human Tissues

    AK006 Inhibits Mast Cell Activation in Human Tissues IgE-Activated Human Tissue Mast Cells AK006 inhibits IgE-mediated mast cell activation Human Tissue Mast Cell Activation Assay n=3 human donors SOURCE: Schanin J, et al. EAACI 2022 Presentation.

  36. Slide 36: AK006 Inhibits KIT-Mediated Mast Cell Activation in Siglec-6 Transgenic Mice

    AK006 Inhibits KIT-Mediated Mast Cell Activation in Siglec-6 Transgenic Mice Mast Cell Activation AK006 inhibits KIT-mediated mast cell activation SCF, stem cell factor; * p < 0.01; n=7-8 mice/group Cytokines and Chemokines CD63 IL-6 TNF CXCL1 / GRO- CCL2 / MCP-1 SOURCE: Korver W, et al. EMBRN 2022

  37. Slide 37: AK006 Reduces IL-33-Mediated Skin Inflammation in Siglec-6 Transgenic Mice

    AK006 Reduces IL-33-Mediated Skin Inflammation in Siglec-6 Transgenic Mice * p < 0.01; n=6 mice/group AK006 inhibits IL-33-mediated inflammation via MC inhibition and reduction Immune Cell Infiltration in Skin Day 0 ISO or AK006 Day 2 Immune cell infiltration in ear Intradermal IL-33 injection IL-33

  38. Slide 38: AK006 Inhibits Allergic Contact Dermatitis in Siglec-6 Transgenic Mice

    AK006 Inhibits Allergic Contact Dermatitis in Siglec-6 Transgenic Mice Skin Inflammation AK006 reduces skin inflammation in mice * p < 0.01; n=6-7 mice/group DNFB, 2,4-dinitrofluorobenzene Cytokines in Ex Vivo-Cultured Ears SOURCE: Allakos Data on File..

  39. Slide 39: Dosing Study in Humanized Mice

    Dosing Study in Humanized Mice AK006 inhibits mast cells and reduces mast cell numbers in preclinical studies Ex Vivo Human Tissue Mast Cells Day 0 Day 15 Dosed with AK006 or AK002 or ISO Control MC numbers Day 5 Day 10 Peritoneal Mast Cells without IFN�� Activated Macrophages with IFN�� Activated M

  40. Slide 40: Financial Overview & Key Milestones

    Financial Overview & Key Milestones

  41. Slide 41: Balance Sheet and IP Protection

    Cash, Cash Equivalents and Investments in Marketable Securities as of June 30, 2022 $212.4 M Common Shares Outstanding 54.8 M First lirentelimab U.S patent to expire in 2035 without extensions Manufacturing lirentelimab at 17K liter scale Balance Sheet and IP Protection

Allakos — Investor Presentation (September 2022) on 6ix